For several years, doctors have actively prescribed glucagon-like peptide-1 (GLP-1) agonists, such as semaglutides (e.g., Ozempic, Wegovy) and tirzepatide (e.g., Mounjaro, Zepbound), to treat type 2 diabetes
The Link Between GLP-1 and Digestive Enzymes The relationship between GLP-1 and digestive enzymes is indirect but functionally significant within the broader context of gastrointestinal physiology
This study was limited in scope: Conducted on 24 rats, not humans Administered a single dose Designed only to demonstrate that some absorption is possible Importantly, the study itself includes this disclaimer: This proof-of-concept study is not intended to provide guidance on the sublingual dosing of semaglutide in humans, or dosing conversion from other forms to sublingual administration. This means the only research behind these products cannot confirm whether they work in humans or provide guidance on appropriate dosing
M., Grill, H
These investigations continue to contribute valuable knowledge regarding peptide-mediated biological processes and molecular signalling mechanisms
Most symptoms improve with dose adjustments